Recent advances in treatment of advanced urothelial carcinoma

Current Urology Reports

Volumn 13, Issue 2, 2012, Pages 147-152

  Kim, Jenny J ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Biomarker; Chemotherapy; Immunotherapy; Targeted therapy; Urothelial carcinoma

Indexed keywords

BCG VACCINE; BEVACIZUMAB; CANCER VACCINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; DENDRITIC CELL VACCINE; DOXORUBICIN; ERIBULIN; ERLOTINIB; GEFITINIB; GEMCITABINE; IPILIMUMAB; IXABEPILONE; LAPATINIB; METHOTREXATE; PACLITAXEL; PEMETREXED; PLACEBO; PLATINUM; SUNITINIB; TRASTUZUMAB; VINBLASTINE; VINFLUNINE;

ADVANCED CANCER; ANEMIA; ANTIANGIOGENIC THERAPY; BLADDER CANCER; BLEEDING; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CYSTECTOMY; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG ERUPTION; FATIGUE; FEBRILE NEUTROPENIA; GENE MUTATION; HUMAN; HYPERTENSION; LUNG EMBOLISM; MELANOMA; MOLECULARLY TARGETED THERAPY; NEUTROPENIA; OVERALL SURVIVAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEINURIA; REVIEW; SIDE EFFECT; SOLID TUMOR; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANCER VACCINES; CARCINOMA, TRANSITIONAL CELL; CISPLATIN; DOXORUBICIN; FEMALE; HUMANS; IMMUNOTHERAPY; MALE; METHOTREXATE; MOLECULAR TARGETED THERAPY; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; QUALITY IMPROVEMENT; QUINAZOLINES; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS; VINBLASTINE;

EID: 84862787781     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-012-0238-0     Document Type: Review

References (47)

1. • Bellmunt J, Théodore C, Demkov T, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol. 2009;27(27):4454. The only phase 3 trial in a second-line setting that evaluated vinflunine is reported in this paper.
2. Galsky MD, Mironov S, Iasonos A, et al. Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma. Invest New Drugs. 2007;25:265.
3. Sweeney CJ, Roth BJ, Kabbinavar FF, et al. Phase II study of pemetrexed for second line treatment of transitional cell cancer of the urothelium. J Clin Oncol. 2006;24:3451.
4. Von der Maase H, Lehmann J, Gravis G, et al. A phase II trial of pemetrexed plus gemcitabine in locally advanced and/or metastatic transitional cell carcinoma of the urothelium. Ann Oncol. 2006;17:1533.
5. Sridhar SS, Canil CM, Mukherjee SD et al. Results of a phase II study of single agent nab-paclitaxel in platinum refractory second line metastatic urothelial carcinoma. J Clin Oncol. 2011;suppl 7, abstract 241.
6. •• Hahn NM, Stadler WM, ZOn RT et al. Phase II Trial of Cisplatin, Gemcitabine, and bevacizumab as first line therapy for metastatic urothelial carcinoma: hoosier oncology Group GU 04-75. J Clin Oncol. 2011. The authors describe a phase 2 study evaluating bevacizumab in combination with chemotherapy. An intergroup trial based on this study is ongoing.
7. National Institutes of Health Clinical Trials database. http://www.clinicaltrials.gov/. Accessed on September 2011.
8. • Bellmunt J, Gonzalez-Larriba JL, Maroto JP et al. First-line treatment with sunitinibmonotherapy in patients with advanced urothelial cancer ineligible for cisplatin-based chemotherapy: Pretreatment levels of IL8 and Hounsfield units as predictors of clinical benefit. J Clin Oncol 28:15s, 2010 (suppl; abstr 4540). This article delineates the efficacy of VEGFR TKI in urothelial carcinoma.
9. Gallagher DJ, Millowsky MI, Gerst SR, et al. A phase II study of sunitinib on a continuous dosing schedule in patients with relapsed or refractory urothelial carcinoma (UC). J Clin Oncol. 2009;27:15s. suppl; abstr 5072.
10. Galsky MD, Sonpavde G, Hellerstedt BA, et al. Phase II study of gemcitabine, cisplatin, and sunitinib in patients with advanced urothelial carcinoma. J Clin Oncol. 2010;28:15s. suppl; abstr 4573.
11. Krege S, Rexer H, vom Dorp F, et al. Gemcitabine and cisplatin with or without sorafenib in urothelial carcinoma (AUO-AB 31/ 05). J Clin Oncol. 2010;28:15s. suppl; abstr 4574.
12. Milowsky MI, Tickoo SK, Gallagher DJ et al. HIF and mTOR pathways in invasive urothelial carcinoma: A study with potential therapeutic implications. J Clin Oncol. 2008. Abstr 292
13. Milowsky MI, Regazzi AM, Garcia-Grossman IR et al. Final results of a phase II study of everolimus (RAD001) in metastatic transitional cell carcinoma (TCC) of the urothelium. J Clin Oncol. 2011;29. (suppl; abstr 4606).
14. • Milowsky MI, Carlson GL, Shi MM et al. A multicenter, openlabel phase II trial of dovitinib (TKI1258) in advanced urothelial carcinoma patients with either mutated or wild-type FGFR3. J Clin Oncol. 2011;29 (suppl; abstr TPS186). This article evaluates another antiangiogenic pathway (FGFR) in treatment of urothelial carcinoma.
15. Daher A, de Boer WI, El-Marjou A, et al. Epidermal growth factor receptor regulates normal urothelial regeneration. Lab Invest. 2003;83:1333.
16. Cheng J, Huang H, Zhang ZT, et al. Overexpression of epidermal growth factor receptor in urothelium elicits urothelial hyperplasia and promotes bladder tumor growth. Cancer Res. 2002;62:4157.
17. Neal DE, Marsh C, Bennett MK, et al. Epidermal growth factor receptors in human bladder cancer: comparison of invasive and superficial tumors. Lancet. 1985;1:366.
18. Berger MS, Greenfield C, Gullick WJ, et al. Evaluation of epidermal growth factor receptors in bladder tumors. Br J Cancer. 1987;56:533.
19. Wong Y, Litwin S, Plimack ER et al. Effect of EGFR inhibition with cetuximab on the efficacy of paclitaxel in previously treated metastatic urothelial cancer.
20. Clinicaltrials.gov. Study of gemcitabine and cisplatin with or without cetuximab in urothelial cancer (NCT00645593). Available at http:// clinicaltrials.gov/ct2/show/NCT00645593. Accessed January 2012.
21. Petrylak DP, Tangen CM, Van Veldhuizen Jr PJ, et al. Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium. BJU Int. 2010;105:317.
22. Philips GK, Halabi S, Sanford BL, et al. A phase II trial of cisplatin, fixed dose-rate gemcitabine and gefitinib for advanced urothelial tract carcinoma: results of the Cancer and Leukemia Group B 90102. BJU Int. 2008;101:20.
23. Philips GK, Halabi S, Sanford BL, et al. A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102. Ann Oncol. 2009;20:1074.
24. Clincialtrials.gov. Gefitinib plus combination chemotherapy in treating patients with locally advanced or metastatic bladder cancer. http://clinicaltrials.gov/ct2/show/NCT00041106. Accessed on January 2012.
25. Hussain MH, MacVicar GR, Petrylak DP, et al. Trastuzumab, paclitaxel, carboplatin and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. J Clin Oncol. 2007;25:2218.
26. Clinicaltrials.gov. Trastuzumab in treating patients with previously treated, locally advanced, or metastatic cancer of the urothelium (NCT00004856). Available at http://clinicaltrials.gov/ct2/show/ NCT00004856. Accessed January 2012.
27. Clinicaltrials.gov. Neoadjuvant Erlotinib (Tarceva) in transitional cell carcinoma (NCT00749892). Available at http://clinicaltrials.gov/ct2/show/ NCT00749892. Accessed January 2012.
28. Clincialtrials.gov. Erlotinib before and after surgery in treating patients with muscle-invasive bladder cancer (NCT00380029). Available at . Accessed January 2012.
29. Sharma P, Shen Y, Wen S, et al. Cancer-testis antigens: expression and correlation with survival in human urothelial carcinoma. Clin Cancer Res. 2006;12:5442.
30. Gnjatic S, Nishikawa H, Jungbluth AA, et al. NY-ESO-1: review of an immunogenic tumor antigen. Adv Cancer Res. 2006;95:1.
31. Sharma P, Gnjatic S, Jungbluth AA, et al. Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1T cell epitope in a patient with bladder cancer. Cancer Immun. 2003;3:19.
32. Sharma P, Shen Y, Wen S, et al. CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci USA. 2007;104:3967.
33. Sharma P, Bajorin DF, Jungbluth AA, et al. Immune response detected in urothelial carcinoma patients after vaccination with NY-ESO-1 protein plus BCG and GM-CSF. J Immunother. 2008;31:849.
34. Sun J, Schiffman J, Raghunath A, et al. Concurrent decrease in IL- 10 with development of immune-related adverse events in a patient treated with anti-CTLA 4 antibody. Cancer Immun. 2008;8:9.
35. Lee JK, Havaleshko DM, Cho H, et al. A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proc Natl Acad Sci USA. 2007;104:13086.
36. Lorenzo-Romero JG, Salinas-Sánchez AS, et al. Prognostic implications of p53 gene mutations in bladder tumors. J Urol. 2003;169 (2):492.
37. Kuczyk MA, Bokemeyer C, Serth J, et al. p53 overexpression as a prognostic factor for advanced stage bladder cancer. Eur J Cancer. 1995;31A(13-14):2243.
38. Edelman MJ, Meyers FJ, Miller TR, et al. Phase I/II study of paclitaxel, carboplatin, and methotrexate in advanced transitional cell carcinoma: a well-tolerated regimen with activity independent of p53 mutation. Urology. 2000;55(4):521.
39. Koga F, Kitahara S, Arai K, Honda M, Sumi S, Yoshida K. Negative p53/positive p21 immunostaining is a predictor of favorable response to chemotherapy in patients with locally advanced bladder cancer. Jpn J Cancer Res. 2000;91(4):416.
40. Sarkis AS, Bajorin DF, Reuter VE, et al. Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. J Clin Oncol. 1995;13(6):1384.
41. • Stadler WM, Lerner SP, Groshen S, et al. Randomized trial of p53 targeted adjuvant therapy for patients with organ-confined node-negative urothelial bladder cancer (abstract #5017). J Clin Oncol. 2009;27:239s. This article describes p53-directed adjuvant therapy in urothelial carcinoma.
42. Kim WJ, Kakehi Y, Yoshida O. Multifactorial involvement of multidrug resistance-associated [correction of resistance]protein, DNA topoisomerase II and glutathione/glutathione-S-transferase in non P-glycoprotein-mediated multidrug resistance in human bladder cancer cells. Int J Urol. 1997;4(6):583-90. (Pubitemid 28021299)
43. Kotoh S, Naito S, Yokomizo A, Kohno K, Kuwano M, Kumazawa J. Enhanced expression of gamma-glutamylcysteine synthetase and glutathione S-transferase genes in cisplatin-resistant bladder cancer cells with multidrug resistance phenotype. J Urol. 1997;157 (3):1054.
44. Pendyala L, Velagapudi S, Toth K, et al. Translational studies of glutathione in bladder cancer cell lines and human specimens. Clin Cancer Res. 1997;3(5):793.
45. Petrylak DP, Scher HI, Reuter V, O'Brien JP, Cordon-Cardo C. Pglycoprotein expression in primary and metastatic transitional cell carcinoma of the bladder. Ann Oncol. 1994;5(9):835.
46. Siegsmund MJ, Marx C, Seemann O, Schummer B, et al. Cisplatin-resistant bladder carcinoma cells: enhanced expression of metallothioneins. Urol Res. 1999;27(3):157.
47. Bellmunt J, Paz-Ares L, Cuello M, Cecere FL, et al. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann Oncol. 2007;18(3):522.